2008: July | April | January
2007: October
2007: March
2007: February
2007: January
2006: December
2006: November
2006: October
2006: July
2006: June
2006: April
2006: March
2006: January
2005: December
2005: November
2005: October
2005: August
2005: July
2005: June
2005: May
2005: April
2005: March
2005: February
2005: January
2004: December
2004: November
2004 International AIDS Conference
2006 Annual Meeting of the Infectious Disease Society of America
2003 Annual Interscience Conference on Antimicrobial Agents and Chemotherapy Meeting
2007 Interscience Conference on Antimicrobial Agents and Chemotherapy
2005 European AIDS Conference
2005 International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV and the 2005 European AIDS Clinical Society Conference
2003 European AIDS Conference
2006 European HIV Drug Resistance Workshop
2004 International Congress on Drug Therapy in HIV Infection
2006 International Congress on Drug Therapy in HIV Infection
2005 International Workshop on Targeting HIV Entry
2004 International Workshop on Adverse Drug Reactions And Lipodystrophy in HIV
2005 International Workshop on Adverse Drug Reactions And Lipodystrophy in HIV
2007 European AIDS Conference
2003 International Conference on Malignancies in AIDS and Other Immunodeficiencies
2008 International AIDS Conference
2004 International Workshop on HIV and Hepatitis Coinfection
2003 International AIDS Society Conference on HIV Pathogenesis and Treatment
2005 International Workshop on Clinical Pharmacology of HIV Therapy
Coverage of the 2006 International Workshop on Clinical Pharmacology of HIV Therapy
2007 International Workshop on Clinical Pharmacology of HIV Therapy
2004 International HIV Drug Resistance Workshop
2005 International HIV Drug Resistance Workshop
2006 International HIV Drug Resistance Workshop
2007 International HIV Drug Resistance Workshop
2003 Conference on Retroviruses and Opportunistic Infections
2004 Conference on Retroviruses and Opportunistic Infections
2005 Conference on Retroviruses and Opportunistic Infections
2006 Conference on Retroviruses and Opportunistic Infections
2007 Conference on Retroviruses and Opportunistic Infections
2008 Conference on Retroviruses and Opportunistic Infections
2005 International AIDS Society Conference on HIV Pathogenesis and Treatment
2004 International Workshop on Clinical Pharmacology of HIV Therapy
2006 Interscience Conference on Antimicrobial Agents and Chemotherapy
4th International AIDS Society Conference on HIV Pathogenesis, Treatment, and Prevention
2006 International AIDS Conference
2005 Interscience Conference on Antimicrobial Agents and Chemotherapy
2004 Annual Interscience Conference on Antimicrobial Agents and Chemotherapy
Conference Calendar
Cardiovascular Risk Factors and Metabolic Complications in Patients Receiving HAART
Dyslipidemia and Other Cardiovascular Risk Factors in HIV: Causes, Clinical Significance, and Management Strategies
Double-Boosted Protease Inhibitors
Fine-Tuning Antiretroviral Therapy in HIV-Infected Patients With Virologic Suppression: Strategies to Address Toxicity, Convenience, and Quality of Life
Fixed-Dose Combination NRTIs in the Treatment of HIV Infection
Choosing an Initial Protease Inhibitor for PI-Naive Patients
Insulin Resistance and Body Shape Changes in HIV-Infected Patients
The Role of Integrase Inhibitors in HIV Management
Strategies for the Management of Multiclass-Resistant Patients
Neurologic Aspects of HIV/AIDS: New Insights and Management Advances
Treatment Strategies With NNRTIs: Use in First-Line vs Later Regimens
NNRTIs in Clinical Practice: An Update
Optimizing the NRTI Backbone in HIV-Infected Patients Receiving Antiretroviral Therapy
The Importance of Pharmacokinetic Factors in Successful Antiretroviral Therapy
Psychiatric Disorders in HIV-Infected Patients
Antiretroviral Resistance and Options for Sequencing
When to Start, What to Use: A Master Class in the Use of First-Line Antiretroviral Therapy
Managing Insulin Resistance in HIV-Infected Patients
Managing Dyslipidemia in HIV-Infected Patients on Therapy: Switch Antiretrovirals or Add Lipid-Lowering Agents?
New Insights Into the Use of PIs Across the Treatment Spectrum
Evolving Concepts in Antiretroviral Therapy
Novel Agents for Treatment-Experienced Patients: Faculty Mentoring for Managing Challenging Cases
Integrating New Antiretroviral Agents Into Therapeutic Strategies for Treatment-Experienced Patients
Answering the Questions: Practical Management Strategies to Address Cardiovascular Risk in HIV
New Classes of Antiretrovirals: The Potential Clinical Role of Integrase Inhibitors and Entry Inhibitors
Managing Cardiovascular Risk in HIV-Infected Patients: The Role of Antiretroviral Selection
New Classes of Antiretrovirals: The Clinical Role of Integrase Inhibitors and Entry Inhibitors
The Clinical Impact of Next-Generation NNRTIs: Recent Research and Practical Treatment Strategies
Evolving Insights Into the Optimal Timing of Antiretroviral Therapy
Rethinking the Role of NNRTIs: Clinical Strategies for Optimizing Outcomes With Next-Generation Agents
Right From the Start: Optimizing First-Line Antiretroviral Therapy
Simple From the Start: The Importance of Treatment Convenience in Antiretroviral Therapy
HIV Entry and Tropism: New Strategies for Effective Antiretroviral Therapy
The New Anatomy of Effective Antiretroviral Therapy
Use of Boosted Protease Inhibitor-Based Regimens in Treatment-Experienced Patients
Managing Metabolic Issues and Cardiovascular Risk in HIV-Infected Patients
Choosing and Using New Antiretrovirals for Multiclass-Experienced HIV-Infected Patients
New Strategies for Regaining Control of HIV Replication in Treatment-Experienced Patients
Understanding HIV Drug Resistance Testing: When to Test, How to Interpret
Managing Drug-Drug Interactions in the Changing Landscape of HIV
Redefining the Frontiers of First-Line Antiretroviral Therapy: A Decade of Progress in Effective HAART
HIV Lessons Learned
Preventing and Managing Antiretroviral Side Effects
Antiretroviral Strategies for the Management of HIV Infection
Metabolic Complications in HIV-Infected Patients
Recent Advances in Managing Neurologic Adverse Effects of Antiretroviral Therapy
New Agents and Treatment Strategies for Treatment-Experienced HIV Patients
New Protease Inhibitors, New Treatment Goals: Attaining Undetectable Viral Load in Antiretroviral-Experienced Patients
New Standards and Strategies in Antiretroviral Therapy
Novel Classes of Antiretrovirals: Update on CCR5 Antagonists and Integrase Inhibitors
The Economics of HIV in the HAART Era
Primary Care and Prevention
Refining Antiretroviral Regimens: Improving Tolerability and Convenience for Virologically Suppressed HIV-Infected Patients
Resistance Testing in HIV
A Decade of HAART: Past, Present, and Future Role of Protease Inhibitors
New and Investigational Anti-HIV Agents: Switching Strategies and Durability
HIV/AIDS Annual Update 2002
HIV/AIDS Annual Update 2003
HIV/AIDS Annual Update 2004
HIV/AIDS Annual Update 2005
HIV/AIDS Annual Update 2006
HIV/AIDS Annual Update 2007
HIV/AIDS Annual Update 2008
From Theory to Practice: Strategies for the Successful Management of Treatment-Experienced Patients
Use of Resistance Testing to Guide Therapy in HIV-Infected Patients with Multiple Regimen Failure
2006: May | April | March | February | January
2005: December
2005: November
2005: October
2005: September
2005: August
2005: July
2005: June
2005: May
2005: April
2005: March
2005: February
2005: January
2004: December
2004: November
2004: October
2004: September
2004: August
2004: July
2004: June
2004: May
2004: April
2004: March
2004: February
2004: January
2003: December
2003: November
2003: October
2003: September
2003: August
2003: July
2003: June
2003: May
2003: April
2003: March
2003: February
Expert Viewpoints
Resources
Animation Downloads
Slideset Downloads
Drugs
Guidelines